Skip to main navigation Skip to search Skip to main content

Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting

  • Valentina Caputo Galarce
  • , K Naresh
  • , O Dubois
  • , MS Chaudhry
  • , M Holubova
  • , S Iles
  • , X Xiao
  • , K Goudevenou
  • , DS Pitcher
  • , K Petevi
  • , J Maher
  • , C Kachramanoglou
  • , N Baxan
  • , A Rotolo
  • , A Karadimitris

Research output: Contribution to journal › Article › peer-review

186 Citations (Scopus)

Abstract

Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical remissions in CD19+ B cell lymphomas are often short lived. We tested whether CAR19-engineering of the CD1d-restricted invariant natural killer T (iNKT) cells would result in enhanced anti-lymphoma activity. CAR19-iNKT cells co-operatively activated by CD1d- and CAR19-CD19-dependent interactions are more effective than CAR19-T cells against CD1d-expressing lymphomas in vitro and in vivo. The swifter in vivo anti-lymphoma activity of CAR19-iNKT cells and their enhanced ability to eradicate brain lymphomas underpinned an improved tumor-free and overall survival. CD1D transcriptional de-repression by all-trans retinoic acid results in further enhanced cytotoxicity of CAR19-iNKT cells against CD19+ chronic lymphocytic leukemia cells. Thus, iNKT cells are a highly efficient platform for CAR-based immunotherapy of lymphomas and possibly other CD1d-expressing cancers.
Original languageEnglish
Pages (from-to)596-610
JournalCancer Cell
DOIs
Publication statusPublished - 8 Oct 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • CAR immunotherapy
  • B cell malignancies
  • iNKT

Fingerprint

Dive into the research topics of 'Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting'. Together they form a unique fingerprint.

Cite this